About the Business

Industry-leading Biotech and Nutraceutical Business for Sale - Australian Biotech Company for Sale - Nutraceutical Business Acquisition - Microbiome Technology Business

A rare chance exists to acquire a pioneering MedTech and nutraceutical enterprise at the forefront of microbiome and DNA technologies. Established for over a decade, this business has built a reputation as a trusted leader in functional pathology and personalised health solutions.

With a robust patent portfolio (including US and EU approvals) and a proprietary curated database delivering clinically validated testing protocols with 99.9% accuracy, the business is uniquely positioned to capitalise on the global surge in gut health, immune support, and precision medicine.

Key Highlights:
* Multiple revenue streams: diagnostic testing, product validation, licensing, R&D partnerships, and practitioner education.
* Market-ready formulations: IBS, autism spectrum, and government/aviation resilience products with annuity-style revenue potential.
* Global scalability: International entity structure enabling seamless access to North American and European markets.
* Strategic partnerships: Accredited facilities across Australia, Canada, and the US, plus established government and institutional relationships.
* Lean, asset-light model: No heavy equipment investment required, ensuring high margins and agility.

Income Potential: While current Net Profit After Tax (NPAT) is $719,614, the true value lies in the pipeline. Conservative modelling shows that even fractional adoption of its patented formulations could generate annual gross profits exceeding $150 million, with high-growth scenarios projecting over $600 million.

Global Market Snapshot:
* Wellness market valued at $1.5 trillion, growing 510% annually.
* Probiotics market valued at USD 87.7 billion (2023), forecast CAGR 14.1% through 2030.
* Immune health supplements market valued at USD 26.6 billion (2023), forecast CAGR 10.7% through 2030.

Independently valued at $29.74M, this business offers extraordinary upside for strategic acquirers with established distribution networks. With the right partner, its pipeline of patented products and validated technologies can be rapidly commercialised to capture a share of these booming global markets.

EXCLUSIVE LISTING WITH NATIONAL BUSINESS SALES & VALUATIONS (Internal Ref: 1140)

Please contact Sam on 1300 89 88 87 to complete confidentiality agreement and receive more information.
Information will be only supplied to QUALIFIED GENUINE BUYERS.

Disclaimer:
The financial information provided is